High serum CEA and CYFRA21-1 levels after a two-cycle adjuvant chemotherapy for NSCLC: possible poor prognostic factors

Cancer Biology and Medicine

Volumn 9, Issue 4, 2012, Pages 270-273

  Lin, Xue Feng ^a   Wang, Xiao Dong ^b   Sun, Da Qiang ^b   Li, Zhi ^b   Bai, Yue ^b  

^a Tianjin Medical College   (China)

^b TIANJIN CHEST HOSPITAL   (China)

Author keywords

Adjuvant chemotherapy; Carcinoembryonic antigen; Cytokeratin 19 fragement; Non small cell lung cancer; Prognosis

Indexed keywords

CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYTOKERATIN 19; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SURVIVAL TIME;

EID: 84876343411     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.7497/j.issn.2095-3941.2012.04.009     Document Type: Article

References (11)

1. Rubins JB, Dunitz J, Rubins HB, et al. Serum carcinoembryonic antigen as an adjunct to preoperative staging of lung cancer. J Thorac Cardiovasc Surg 1998; 116: 412-416.
2. Kawachi R, Nakazato Y, Takei H, et al. Clinical significance of preoperative carcinoembryonic antigen level for clinical stage I non-small cell lung cancer: Can preoperative carcinoembryonic antigen level predict pathological stage? Interact Cardiovasc Thorac Surg 2009; 9: 199-202.
3. Ishiguro F, Fukui T, Mori S, et al. Serum carcinoembryonic antigen level as an surrogate marker for the evaluation of tumor response to chemotherapy in nonsmall cell lung cancer. Ann Thorac Cardiovasc Surg 2010; 16: 242-247.
4. Tomita M, Matsuzaki Y, Edagawa M, et al. Prognostic significance of preoperative serum carcinoembryonic antigen level in lung adenocarcinoma but not squamous cell carcinoma. Ann Thorac Cardiovasc Surg 2004; 10: 76-80.
5. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343-346.
6. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-360.
7. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: A decade of progress. Chest 2002; 122: 1037-1057.
8. Boffa DJ. The revised stage classifi cation system for primary lung cancer. Clin Chest Med 2011; 32: 741-748.
9. Nisman B, Biran H, Heching N, et al. Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: Association of marker changes after two chemotherapy cycles with different measures of clinical response and survival. Br J Cancer 2008; 98: 77-79.
10. Wang J, Zhang N, Li B, et al. Decline of serum CYFRA21-1 during chemoradiotherapy of NSCLC: A probable predictive factor for tumor response. Tumor Biol 2011; 32: 689-695.
11. Pujol JL, Molinier O, Ebert W, et al. CYFRA21-1 is a prognostic determinant in non-small-cell lung cancer: Results of a metaanalysis in 2063 patients. Br J Cancer 2004; 90: 2097-2105.